A pivotal Phase III study of lurbinectedin in patients with of BRCA2 mutated breast cancer
Phase of Trial: Phase III
Latest Information Update: 04 Nov 2017
At a glance
- Drugs Lurbinectedin (Primary)
- Indications Breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors PharmaMar
- 04 Nov 2017 According to a PharmaMar media release, this trial is expected to begin in 2018.
- 26 May 2017 New trial record
- 19 May 2017 According to a PharmaMar media release, the company has reached an agreement with the US FDA on the design of this study.